Jorge Maspero
Overview
Explore the profile of Jorge Maspero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1624
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gevaert P, Desrosiers M, Cornet M, Mullol J, De Corso E, Keles Turel N, et al.
Lancet
. 2025 Mar;
405(10482):911-926.
PMID: 40037388
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms are frequently driven by type 2 inflammation. Depemokimab is the first ultra-long-acting biological drug engineered with enhanced interleukin-5 binding affinity, high potency,...
2.
Larenas-Linnemann D, Rhee C, Altraja A, Busby J, Tran T, Wang E, et al.
Tuberc Respir Dis (Seoul)
. 2025 Feb;
PMID: 39915034
The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As the first global registry...
3.
Maspero J, de Paula Motta Rubini N, Zhang J, Sanclemente G, Amador J, El Sayed M, et al.
World Allergy Organ J
. 2024 Nov;
17(11):100966.
PMID: 39568731
[This corrects the article DOI: 10.1016/j.waojou.2022.100724.].
4.
Pavord I, Chan R, Brown N, Howarth P, Gilson M, Price R, et al.
Ann Med
. 2024 Oct;
56(1):2417184.
PMID: 39465531
Objectives: Long-term safety monitoring of mepolizumab is necessary to support real-world use for the treatment of severe asthma. This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in...
5.
Denton E, Hew M, Peters M, Upham J, Bulathsinhala L, Tran T, et al.
Allergy
. 2024 Jun;
79(10):2700-2716.
PMID: 38923444
Background: Biologic asthma therapies reduce exacerbations and long-term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence,...
6.
Porsbjerg C, Townend J, Bergeron C, Christoff G, Katsoulotos G, Larenas-Linnemann D, et al.
Front Immunol
. 2024 May;
15:1361891.
PMID: 38711495
Background: To date, studies investigating the association between pre-biologic biomarker levels and post-biologic outcomes have been limited to single biomarkers and assessment of biologic efficacy from structured clinical trials. Aim:...
7.
Lee T, Price D, Yadav C, Roy R, Lim L, Wang E, et al.
Chest
. 2024 Feb;
166(1):28-38.
PMID: 38395297
Background: Exacerbation frequency strongly influences treatment choices in patients with severe asthma. Research Question: What is the extent of the variability of exacerbation rate across countries and its implications in...
8.
Chen W, Tran T, Sadatsafavi M, Murray R, Boon Wong N, Ali N, et al.
J Allergy Clin Immunol Pract
. 2024 Feb;
12(2):536-539.
PMID: 38336403
No abstract available.
9.
Perez-de-Llano L, Scelo G, Canonica G, Chen W, Henley W, Larenas-Linnemann D, et al.
Ann Allergy Asthma Immunol
. 2023 Dec;
132(5):610-622.e7.
PMID: 38151100
Background: There is little agreement on clinically useful criteria for identifying real-world responders to biologic treatments for asthma. Objective: To investigate the impact of pre-biologic impairment on meeting domain-specific biologic...
10.
Wechsler M, Scelo G, Larenas-Linnemann D, Torres-Duque C, Maspero J, Tran T, et al.
Am J Respir Crit Care Med
. 2023 Nov;
209(3):262-272.
PMID: 38016003
Previous studies investigating the impact of comorbidities on the effectiveness of biologic agents have been relatively small and of short duration and have not compared classes of biologic agents. To...